| ［1］ |
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts［J］. J Am Acad Dermatol, 2020,82（3）:575⁃585.e1. doi: 10.1016/j.jaad.2018.02.021.
|
| ［2］ |
Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies［J］. J Hematol Oncol, 2009,2:36. doi: 10.1186/1756⁃8722⁃2⁃36.
|
| ［3］ |
Zhang B, Mao X, Zhao W, et al. Successful treatment with thalidomide for pemphigus vulgaris［J］. Ther Adv Chronic Dis, 2020,11:2040622 320916023. doi: 10.1177/2040622320916023.
|
| ［4］ |
常慧玲, 陈喜雪, 朱学骏, 等. 沙利度胺治疗天疱疮口腔黏膜损害的疗效及安全性［J］. 临床皮肤科杂志, 2020,49（9）:518⁃520. doi: 10.16761/j.cnki.1000⁃4963.2020.09.003.
|
| ［5］ |
Zader J, Vucinic V, Simon JC, et al. Recalcitrant pemphigus successfully treated with lenalidomide［J］. Eur J Dermatol, 2020,30（2）:178⁃179. doi: 10.1684/ejd.2020.3715.
|
| ［6］ |
Harman KE, Gratian MJ, Shirlaw PJ, et al. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris［J］. Br J Dermatol, 2002,146（4）:684⁃687. doi: 10.1046/j.1365⁃2133.2002.04608.x.
|
| ［7］ |
Wang M, Li J, Shang P, et al. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission［J］. J Dermatol, 2023,50（10）:1347⁃1352. doi: 10.1111/1346⁃8138. 16838.
|
